Credit Suisse’s Tvardi Therapeutics TVRD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,489
| Closed | -$440K | – | 3281 |
|
|
2023
Q1 | $440K | Buy |
2,489
+71
| +3% | +$23.8K | ﹤0.01% | 2818 |
|
|
2022
Q4 | $935K | Buy |
2,418
+1,087
| +82% | +$413K | ﹤0.01% | 2385 |
|
|
2022
Q3 | $448K | Buy |
1,331
+8
| +0.6% | +$2.9K | ﹤0.01% | 2853 |
|
|
2022
Q2 | $435K | Sell |
1,323
-40
| -3% | -$14K | ﹤0.01% | 2931 |
|
|
2022
Q1 | $596K | Sell |
1,363
-15
| -1% | -$6.16K | ﹤0.01% | 2872 |
|
|
2021
Q4 | $605K | Buy |
1,378
+131
| +11% | +$65.8K | ﹤0.01% | 3677 |
|
|
2021
Q3 | $694K | Sell |
1,247
-121
| -9% | -$60.7K | ﹤0.01% | 3591 |
|
|
2021
Q2 | $702K | Buy |
1,368
+238
| +21% | +$151K | ﹤0.01% | 3621 |
|
|
2021
Q1 | $882K | Sell |
1,130
-256
| -18% | -$175K | ﹤0.01% | 3402 |
|
|
2020
Q4 | $755K | Buy |
1,386
+444
| +47% | +$233K | ﹤0.01% | 3543 |
|
|
2020
Q3 | $431K | Sell |
942
-90
| -9% | -$52.3K | ﹤0.01% | 3468 |
|
|
2020
Q2 | $635K | Buy |
1,032
+382
| +59% | +$211K | ﹤0.01% | 3183 |
|
|
2020
Q1 | $309K | Sell |
650
-97
| -13% | -$52.7K | ﹤0.01% | 3409 |
|
|
2019
Q4 | $433K | Buy |
747
+7
| +0.9% | +$4.91K | ﹤0.01% | 3650 |
|
|
2019
Q3 | $487K | Buy |
740
+212
| +40% | +$176K | ﹤0.01% | 3457 |
|
|
2019
Q2 | $408K | Sell |
528
-112
| -18% | -$78.7K | ﹤0.01% | 3520 |
|
|
2019
Q1 | $453K | Sell |
640
-94
| -13% | -$56.3K | ﹤0.01% | 3389 |
|
|
2018
Q4 | $343K | Buy |
734
+231
| +46% | +$149K | ﹤0.01% | 3458 |
|
|
2018
Q3 | $434K | Sell |
503
-172
| -25% | -$124K | ﹤0.01% | 3375 |
|
|
2018
Q2 | $466K | Sell |
675
-170
| -20% | -$86.4K | ﹤0.01% | 3458 |
|
|
2018
Q1 | $377K | Sell |
845
-887
| -51% | -$430K | ﹤0.01% | 3491 |
|
|
2017
Q4 | $763K | Buy |
1,732
+341
| +25% | +$155K | ﹤0.01% | 3184 |
|
|
2017
Q3 | $687K | Sell |
1,391
-1,116
| -45% | -$559K | ﹤0.01% | 3353 |
|
|
2017
Q2 | $1.39M | Buy |
+2,507
| New | +$1.59M | ﹤0.01% | 2475 |
|
|
2017
Q1 | – | Sell |
-435
| Closed | -$145K | – | 4115 |
|
|
2016
Q4 | $145K | Sell |
435
-23
| -5% | -$7.38K | ﹤0.01% | 3888 |
|
|
2016
Q3 | $138K | Sell |
458
-268
| -37% | -$58.1K | ﹤0.01% | 3881 |
|
|
2016
Q2 | $125K | Buy |
726
+201
| +38% | +$43.8K | ﹤0.01% | 4019 |
|
|
2016
Q1 | $118K | Buy |
+525
| New | +$157K | ﹤0.01% | 3801 |
|
|
2015
Q4 | – | Sell |
-278
| Closed | -$143K | – | 4388 |
|
|
2015
Q3 | $143K | Sell |
278
-483
| -63% | -$323K | ﹤0.01% | 4036 |
|
|
2015
Q2 | $333K | Buy |
761
+78
| +11% | +$30.1K | ﹤0.01% | 3968 |
|
|
2015
Q1 | $247K | Buy |
+683
| New | +$258K | ﹤0.01% | 3972 |
|
|
2014
Q4 | – | Sell |
-552
| Closed | -$166K | – | 4772 |
|
|
2014
Q3 | $166K | Buy |
+552
| New | +$227K | ﹤0.01% | 4194 |
|
Other funds holding TVRD
DGI
FCM
C
BCLSI
Credit Suisse's TVRD Position: Q2 2023 in Review
Credit Suisse sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 2,489 shares — an estimated $440K sold.
Credit Suisse first reported a position in TVRD in Q3 2014 and held it in 32 quarters. The position peaked at $1.39M in Q2 2017. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.
- Credit Suisse reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
- Credit Suisse sold 2,489 Tvardi Therapeutics shares in Q2 2023, an estimated $440K.
- Credit Suisse first reported a position in Tvardi Therapeutics in Q3 2014 and held it in 32 quarters.
- Credit Suisse's Tvardi Therapeutics position peaked at $1.39M in Q2 2017.
- 136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.
Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.